Mechanisms of AS01B Adjuvant in CD4 T Cell Activation

AS01B adjuvant mechanisms and CD4 T cell responses

AS01B induces robust and durable CD4 T cell responses via a two-phase mechanism of transient inflammatory cytokine induction followed by sustained IFN-signaling pathway activation that drives context-dependent Th1 or Th2 polarization.

Abstract

AS01B adjuvant induces CD4 T cell responses through a two-phase mechanism involving initial transient inflammatory activation followed by sustained IFN-signaling pathway engagement. Studies demonstrate that AS01B triggers early innate responses including IL-6 and CRP peaking at 24 hours post-vaccination, followed by IFN-γ upregulation and activation of IFN-inducible genes (STAT1, IRF1, MX1, CXCL10) after the second dose. This innate activation directly correlates with enhanced CD4+ T cell outcomes, as multi-parametric modeling shows associations between CRP, IL-6, IFN-signaling pathway activation and subsequent CD4 responses. AS01B consistently induces superior CD4 T cell responses compared to AS02A (3.1-fold higher frequencies), AS03 (5.4-fold higher), AS04 (2.8-fold higher), and aluminum adjuvants, with exceptional durability extending 18-36+ months post-vaccination.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question. More on methods

Records from Elicit search

• n = 200
• Papers screened using: AS01B Adjuvant Focus, CD4 T Cell Response Measurement, Appropriate Study Type, AS01B Data Availability, CD4 T Cell Data Inclusion, CD4 T Cell Response Focus, AS01B Effect Attribution, Full Publication Status
• n = 200 Papers screened out
• n = 190 Papers included for extraction

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

We ran this query: “AS01B adjuvant mechanisms and CD4 T cell responses”

The search returned 200 total results from Elicit.

Screening

We screened in sources based on their abstracts that met these criteria:

• AS01B Adjuvant Focus: Does this study investigate AS01B adjuvant specifically (containing MPL and QS-21 in liposomes)?
• CD4 T Cell Response Measurement: Does this study measure CD4 T cell responses as primary or secondary outcomes (including CD4 T cell activation, proliferation, cytokine production, memory formation, or phenotypic characterization)?
• Appropriate Study Type: Is this study either a human clinical trial (Phase I, II, III, or IV) or an animal study using established laboratory models?
• AS01B Data Availability: Does this study include AS01B data (rather than focusing solely on other AS adjuvant systems like AS01E, AS02, AS03, or AS04 without any AS01B data)?
• CD4 T Cell Data Inclusion: Does this study include CD4 T cell data (rather than measuring only antibody responses without any CD4 T cell data)?
• CD4 T Cell Response Focus: Does this study include CD4 T cell response data (rather than focusing exclusively on CD8 T cell or innate immune responses without any CD4 T cell data)?
• AS01B Effect Attribution: Can the AS01B adjuvant effects be separated and attributed specifically to AS01B in this study (rather than being confounded with other interventions)?
• Full Publication Status: Is this a full-text publication (rather than only a conference abstract without full publication)?

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.

Results

Characteristics of included studies

AS01B mechanisms at the innate immunity level

Study

CD4 T cell responses induced by AS01B

Study

Comparative adjuvant effects

Mechanistic links between AS01B activation and CD4 T cell responses

Burny et al. provided the most direct evidence connecting AS01B’s innate mechanisms to CD4 outcomes through multi-parametric modeling. The study demonstrated associations between adaptive CD4+ T-cell responses and specific innate traits post-dose 2, particularly activation of the IFN-signaling pathway, CRP responses, and IL-6 responses. The temporal relationship showed increased IFN-γ levels after the second injection correlating with enhanced CD4+ T-cell responses. The authors proposed “trained immunity” and CD4+ T-cell regulation as potential mechanisms linking innate responses to sustained CD4+ T-cell responses.

Nielsen et al. revealed that AS01B’s promotion of a Th2 response was mechanistically linked to better B cell help and antibody production. The platform induced higher magnitude antigen-specific cTfh cells, which correlated with humoral immunity markers including IgG concentrations and memory B cell frequencies. RNA-seq data showed higher expression of genes related to Tfh and Th2 cell differentiation in AS01B vaccinees, providing a mechanistic basis for the observed Th2 bias.

The dose-response relationship between AS01B components and CD4 responses was evident in the AS01E comparison. AS01B contains twice the amount of MPL and QS-21 as AS01E, and this correlated with higher CD4 T-cell responses. The synergistic combination of MPL and QS-21 appeared critical, as studies consistently emphasized their combined effect in inducing CD4 responses.

Brando et al. provided cellular-level evidence that CD4+ cells were the main IFN-γ-producing splenocytes in response to AS01B immunization, establishing a direct causal link between AS01B and CD4+ T cell activation. However, blocking anti-CD4+ antibody experiments indicated other cell types also contributed to IFN-γ production, suggesting AS01B activates multiple cellular pathways.

Synthesis

The evidence reveals AS01B functions through a two-phase mechanism linking innate activation to durable CD4 responses. In the innate phase, AS01B induces transient inflammatory mediators (IL-6, CRP) peaking at 24 hours, followed by delayed IFN-signaling pathway activation after the second dose (days 31-33). This innate activation then drives robust CD4 T cell responses characterized by high magnitude, extended durability (18+ months), and context-dependent Th1/Th2 polarization.

The Th1/Th2 skewing appears platform-dependent rather than contradictory. Protein/AS01B formulations induced Th2/Tfh2-biased responses with enhanced humoral immunity, while most other contexts showed strong Th1 responses. This likely reflects differential pathway activation: PPAR, FcεRI, and TGF-β pathways were upregulated with protein/AS01B, while IFN-signaling dominated in other formulations. Both patterns ultimately enhanced vaccine immunogenicity through complementary mechanisms—Th1 for cellular immunity and Th2 for antibody production.

AS01B’s superiority over AS02A formulations (efficacy 50% vs 32%; 3.1-fold more CD4 cells) likely stems from its liposomal versus emulsion-based delivery of MPL/QS-21. The dose-response relationship is evident: AS01E with half the MPL/QS-21 induced 2.2-fold lower CD4 responses, despite comparable innate profiles. This suggests AS01B’s enhanced efficacy requires both optimal component dosing and liposomal formulation for maximal CD4 activation.

The mechanistic link between innate and adaptive responses is supported by modeling showing CRP, IL-6, and IFN-signaling pathway activation post-dose 2 predicting CD4+ T-cell outcomes. The delayed IFN-γ increase after the second injection suggests a priming-boosting mechanism where initial innate activation conditions the immune system for enhanced CD4 responses upon rechallenge. This explains AS01B’s exceptional durability—responses persisted 3+ years versus weeks for many adjuvants—likely through establishment of long-lived memory CD4+ T cells promoted by sustained IFN-γ production.